Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS
In conclusion, these post hoc analyses indicate that effects of sc IFN β-1a 44 µg tiw on clinical/MRI endpoints are preserved in a patient subgroup appearing to transition between RRMS and SPMS. (Source: Journal of Neurology)
Source: Journal of Neurology - September 25, 2019 Category: Neurology Source Type: research
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register
ConclusionThe ideal treatment option for MS is becoming increasingly complex, with the need to balance benefit and risks. Our results suggest that starting with FTY affects the long-term disease outcome similarly to escalating from IFN- β1a to FTY. (Source: Journal of Neurology)
Source: Journal of Neurology - September 17, 2019 Category: Neurology Source Type: research
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Publication date: Available online 3 September 2019Source: The Lancet NeurologyAuthor(s): Giancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree, James K Sheffield, Neil Minton, Kartik Raghupathi, Ning Ding, Jeffrey A Cohen, SUNBEAM Study InvestigatorsSummaryBackgroundOzanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable s...
Source: The Lancet Neurology - September 5, 2019 Category: Neurology Source Type: research
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Publication date: Available online 3 September 2019Source: The Lancet NeurologyAuthor(s): Jeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree, James K Sheffield, Neil Minton, Kartik Raghupathi, Vivian Huang, Ludwig Kappos, RADIANCE Trial InvestigatorsSummaryBackgroundOzanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ...
Source: The Lancet Neurology - September 5, 2019 Category: Neurology Source Type: research
Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
Conclusions
Although the primary end point was not met, these data suggest a potential treatment effect of cholecalciferol in patients with RRMS already treated with interferon beta-1a and low serum 25OHD concentration. Together with the good safety profile, these data support the exploration of cholecalciferol treatment in such patients with RRMS.
Clinicaltrials.gov identifier
NCT01198132.
Classification of evidence
This study provides Class II evidence that for patients with RRMS and low serum 25OHD, cholecalciferol did not significantly affect ARRs. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - August 5, 2019 Category: Neurology Authors: Camu, W., Lehert, P., Pierrot-Deseilligny, C., Hautecoeur, P., Besserve, A., Jean Deleglise, A.-S., Payet, M., Thouvenot, E., Souberbielle, J. C. Tags: Clinical trials Randomized controlled (CONSORT agreement), Multiple sclerosis Article Source Type: research
Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis.
CONCLUSION: Sesame oil, through a decrease in IFN-γ secretion and anti-inflammatory and anti-oxidant activities, may have beneficial effects for MS patients.
PMID: 31331574 [PubMed - in process] (Source: Complementary Therapies in Medicine)
Source: Complementary Therapies in Medicine - July 25, 2019 Category: Complementary Medicine Authors: Faraji F, Hashemi M, Ghiasabadi A, Davoudian S, Talaie A, Ganji A, Mosayebi G Tags: Complement Ther Med Source Type: research
Patients’ Preferences and Willingness-to-Pay for Disease-Modifying Therapies
ConclusionsPatients with MS considered relapse rate, disability progression, severe adverse events, route of administration, frequency of administration, and out-of-pocket cost, when they chose DMTs. Their WTPs for DMTs varied widely. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - July 10, 2019 Category: Neurology Source Type: research
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
This study is registered at ClinicalTrials.gov, number NCT01864148.FindingsBetween Aug 13, 2013, and July 31, 2014, 419 patients were enrolled and randomly assigned either placebo (n=93) or opicinumab 3 mg/kg (n=45), 10 mg/kg (n=95), 30 mg/kg (n=94; one patient did not receive the assigned treatment), or 100 mg/kg (n=92). The last patient visit was on March 29, 2016. Confirmed disability improvement over 72 weeks was seen in 45 (49%) of 91 patients assigned to placebo, 21 (47%) of 45 assigned to opicinumab 3 mg/kg, 59 (63%) of 94 assigned to opicinumab 10 mg/kg, 59 (65%) of 91 assigned to opicinumab 30 mg/kg, and 36 (40%) ...
Source: The Lancet Neurology - July 6, 2019 Category: Neurology Source Type: research
Cladribine (Mavenclad) for Multiple Sclerosis
Date: July 29, 2019
Issue #:
1577Summary:
The FDA has approved cladribine (Mavenclad– EMD
Serono), a purine antimetabolite, for oral treatment
of adults with relapsing forms of multiple sclerosis
(MS), including relapsing-remitting disease and
active secondary progressive MS (SPMS), who
cannot tolerate or have had an inadequate response
to other drugs indicated for treatment of M S. It is
not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved
for treatment of hairy cell leukemia, has been
used off-label for treatment of...
Source: The Medical Letter - June 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Cladribine Copaxone dimethyl fumarate Fingolimod Gilenya Glatiramer acetate Interferon beta Lemtrada Mavenclad Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Plegridy siponimod T Source Type: research
Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
We report a case of tumefactive demyelination (TD) in an ocrelizumab-treated patient with RRMS. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - June 25, 2019 Category: Neurology Authors: Moreira Ferreira, V. F., Meredith, D., Stankiewicz, J. M. Tags: Clinical neurology history, Multiple sclerosis Clinical/Scientific Notes Source Type: research
Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
Conclusion: Patients with isolated thalamic atrophy were at a higher risk for not reaching 2-year NEDA-3 and for EDSS increase than patients with no identified brain atrophy. The groups were clinically indistinguishable. A single measurement of thalamic and whole brain atrophy could help identify patients needing most effective therapies from early on.
Introduction
The quantification of brain atrophy by MRI has become an increasingly important part of evaluating neurodegeneration in MS (1, 2). Atrophy measures can reflect the damage on the central nervous system (CNS) caused by the pathological processes of the dis...
Source: Frontiers in Neurology - May 2, 2019 Category: Neurology Source Type: research
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
Date: May 6, 2019
Issue #:
1571Summary:
The FDA has approved siponimod (Mayzent–
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing
forms of multiple sclerosis (MS), including clinically
isolated syndrome (initial neurological episode),
relapsing-remitting disease, and active secondary
progressive MS (SPMS). Siponimod i s the second
S1P receptor modulator to be approved in the US;
fingolimod(Gilenya), which is approved for oral
treatment of relapsing forms of MS in patients≥10
years old, was the first. The purine antime...
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Cladribine dimethyl fumarate Fingolimod Gilenya Glatect Glatiramer acetate Glatopa interferod beta Lemtrada Mavenclad Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Plegridy sipo Source Type: research
Successful intravenous immunoglobulin treatment in relapsing mog-antibody-associated disease
Publication date: Available online 15 April 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Elena Tsantes, Erica Curti, Ernesto Siena, Franco GranellaAbstractTreatment of MOG Ab-associated disease is poorly standardized: several drugs have been employed, with variable results. A 50-year-old Caucasian male was admitted to hospital in 2009, with severe acute transverse myelitis. A brain and spinal cord MRI showed multiple demyelinating lesions and cerebrospinal fluid analysis revealed no oligoclonal bands (OCBs). A diagnosis of multiple sclerosis (MS) was made. He was treated with interferon-beta 1a, then with...
Source: Multiple Sclerosis and Related Disorders - April 17, 2019 Category: Neurology Source Type: research
The Cerebrospinal Fluid in Multiple Sclerosis
Conclusions
OCB are important biomarkers that can support MRI diagnostics and help to avoid false-positive MS diagnoses. Therefore, the revised McDonalds criteria have increased the importance of the OCB.
New biomarkers such as AQP4 have now established themselves in clinical practice, and others such as Anti-MOG and NfL are about to enter clinical routine.
An important focus in the search for new biomarkers is the monitoring of therapy efficacy and the prediction of severe side effects.
Many other CSF molecules such as CHI3L1, IL-6, or CXCL13 show potential as markers for clinical practice, but further research is nee...
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research
Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1 H-NMR Spectroscopy
In conclusion, a metabolomic approach appears to be a promising, noninvasive tool that could potentially contribute to predicting the efficacy of MS therapies. (Source: Neurotherapeutics)
Source: Neurotherapeutics - February 28, 2019 Category: Neurology Source Type: research
